Study of Copanlisib in Hepatic or Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

March 13, 2020

Study Completion Date

May 15, 2020

Conditions

Hepatic Insufficiency, Renal Insufficiency

Interventions

DRUG

Copanlisib (ALIQOPA, BAY80-6946)

12mg single dose, intravenous on Day 0

Trial Locations (2)

CRS Clinical-Research-Services Kiel GmbH, Kiel

Institutul National de Boli Infectioase Prof.Dr.Matei Bals, Bucharest